Today's top medical abstracts
Oncology
Become a Member Today!
Email
Password
Remember me
Forgot your Password?

Invite Code?

Home
General Oncology
For Practicing
Oncologists
Conferences
Jobs
Newsletters
My Library
Topics in
Oncology
        Alternative Therapies
        Anemia/Polycythemia
        BMT/SCT
        Basic Science/Genetics
        Bone/Cartilage
        Breast
        Carcinogenesis
        Coagulation/Bleeding Dz
        Colorectal Cancer/Polyps
        Dermatologic Oncology
        Diagnostics/Radiology
        Economics of Medicine
        Endocrine Oncology
        GI Oncology
        Gynecologic Oncology
        Head and Neck
        Hepatobiliary/Pancreas
        Leukemia/Lymphoma
        Lung/Thoracic Oncology
        Myeloproliferative Dz
        Neurologic Oncology
        Pain/Palliative Care
        Pediatric Heme/Oncology
        Pharmacology/Therapy
        Popular Press
        Renal/Urologic
        Side Effects
        Soft Tissue/Sarcoma
        Transfusion Medicine
 
Help
Resource Center
RSS News Feeds
Send Newsletter
to a Friend
 
Sponsor
For Practicing Oncologists
Technology Advances: Next-Generation Diagnostics Offer On-the-Spot Results
Dorothy J. Schirf, MD, MDLinx Oncology
Off-Label Use: Sitting In Limbo
Roberta Buell, MBA, Sausalito Healthcare Partners
Clinical Trial Watch: Trial Finds Virtual Colonoscopy Comparable to Standard Colonoscopy
Tracy Hampton, PhD, MDLinx Oncology
  See all
breast cancer;comparative actions of hormones Article Summary

Click the title below to leave the MDLinx Network and go to the Journal's Website
Comparative actions of progesterone, medroxyprogesterone acetate, drospirenone and nestorone on breast cancer cell migration and invasion
BMC Cancer, 06/20/08
Print     Email This Article     Save in My Library   Free Abstract
Xiao-Dong F et al. - In a study to investigate the effects of progesterone (P), medroxyprogesterone acetate (MPA), drospirenone (DRSP), and nestorone (NES) alone or with 17beta-estradiol (E2) on T47-D breast cancer cell migration and invasion, these results imply that P, MPA, DRSP, and NES alone or in combination with E2 enhance the ability of breast cancer cells to move in the surrounding environment. These findings support the concept that each progestin acts differently on breast cancer cells

Methods
  • The effects of progesterone (P), medroxyprogesterone acetate (MPA), drospirenone (DRSP) and nestorone (NES) alone or with 17beta-estradiol (E2) were investigated on T47-D breast cancer cell migration and invasion
  • Some of these actions were linked to regulation of the actin-regulatory protein, moesin and to cytoskeletal remodeling

Results
  • Breast cancer cell horizontal migration and invasion of 3-dimensional matrices are enhanced by all the progestins, but differences are found in terms of potency, with MPA being the most effective and DRSP being the least
  • This is related to the differential ability of the progestins to activate the actin-binding protein moesin, leading to distinct effects on actin cytoskeleton remodeling and on formation of cell membrane structures that mediate cell movement
  • E2 also induces actin remodeling through moesin activation
  • The addition of some progestins partially offsets the action of estradiol on cell migration and invasion of breast cancer cells

Sponsor
Read a Different Specialty
Allergy/Immunology
Anesthesiology
Cardiology
Dermatology
Drugs
Emergency Medicine
Endocrinology
ENT
Family Medicine
Gastroenterology
Hematology-Oncology
Infectious Disease
Internal Medicine
Nephrology
Neurology
OB/Gyn
Ophthalmology
Orthopedics
Pediatrics
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology
Profession Index
Dentist
Hospital Administrator
Nurse
    Medical Students
Nurse Practitioner
Pharma/Drug Marketer
    Pharmacist
Physician
Physician Assistants
Article Search
Keyword:
Search:
Published within:
Sort By:
Date Relevance
    
Sponsor
Sponsor
About MDLinx  |  Contact  |  Advertise with MDLinx  |  Site Map  |  Privacy Policy  |  Terms of Use  |  Sign Up For Newsletters  |  Recommend this Site

English |  Español |  Français |  Deutsch |  中文 |  Руccкий |  Norsk |  Nederlands |  Português |  Italiano

©1999-2008 MDLinx, Inc.